Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
L
Li-Bo Tang
Y
Ying-Long Peng
J
Ji Chen
J
Jia-Ting Li
M
Mei-Mei Zheng
L
Lv Wu
C
Chang Lu
X
Xue-Wu Wei
D
Dong-Xuan Cai
Z
Zhi Guo
Z
Zi-Rui Ren
S
Si-Di Lv
Y
Yu Deng
Z
Zhi-Hong Chen
C
Chong-Rui Xu
Q
Qing Zhou
Article Details
Journal
Nature Reviews Clinical Oncology
Volume / Issue
Vol. 22, Issue 8
Published
August 01, 2025
Pages
546-565
ISSN
1759-4774
Publisher
Springer Science and Business Media LLC
Journal Info
Nature Reviews Clinical Oncology
Springer Science and Business Media LLC
ISSN: 1759-4774 Q1 Medicine
Authors (16)
L
Li-Bo Tang
Y
Ying-Long Peng
J
Ji Chen
J
Jia-Ting Li
M
Mei-Mei Zheng
L
Lv Wu
C
Chang Lu
X
Xue-Wu Wei
D
Dong-Xuan Cai
Z
Zhi Guo
Z
Zi-Rui Ren
S
Si-Di Lv
Y
Yu Deng
Z
Zhi-Hong Chen
C
Chong-Rui Xu
Q
Qing Zhou
Related Articles from this Journal
Ibrutinib improves overall survival in patients with mantle cell lymphoma
Peter Sidaway
Jul 2026
10.1038/s41571-026-01166-7
First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA
Diana Romero
Jul 2026
10.1038/s41571-026-01169-4
Clinical implementation of multi-cancer early detection tests: can we find a path forward?
Ariadna Tibau, Aaron S. Kesselheim
Jul 2026
10.1038/s41571-026-01158-7
Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer
David Killock
Jul 2026
10.1038/s41571-026-01162-x
Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer
W. K. Jacky Lam, Brigette B. Y. Ma
Jul 2026
10.1038/s41571-026-01157-8